Pediatric drug overdose mortality: contextual and policy effects for children under 12 years.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
19
10
2020
accepted:
19
04
2021
revised:
10
03
2021
pubmed:
23
5
2021
medline:
26
3
2022
entrez:
22
5
2021
Statut:
ppublish
Résumé
We determine trends in fatal pediatric drug overdose from 1999 to 2018 and describe the influence of contextual factors and policies on such overdoses. Combining restricted CDC mortality files with data from other sources, we conducted between-county multilevel models to examine associations of demographic and socioeconomic characteristics with pediatric overdose mortality and a fixed-effects analysis to identify how changes in contexts and policies over time shaped county-level fatal pediatric overdoses per 100,000 children under 12 years. Pediatric overdose deaths rose from 0.08/100,000 children in 1999 to a peak of 0.19/100,000 children in 2016, with opioids accounting for an increasing proportion of deaths. Spatial patterns of pediatric overdose deaths are heterogenous. Socioeconomic characteristics are not associated with between-county differences in pediatric overdose mortality. Greater state expenditures on public welfare (B = -0.099; CI: [-0.193, -0.005]) and hospitals (B = -0.222; CI: [-.437, -.007]) were associated with lower pediatric overdose mortality. In years when a Good Samaritan law was in effect, the county-level pediatric overdose rate was lower (B = -0.095; CI: [-0.177, -0.013]). Pediatric overdose mortality increased since 1999, peaking in 2016. Good Samaritan laws and investment in hospitals and public welfare may temper pediatric overdoses. Multi-faceted approaches using policy and individual intervention is necessary to reduce pediatric overdose mortality. Pediatric fatalities from psychoactive substances have risen within the U.S. since 1999. Higher levels of state spending on public welfare and hospitals are significantly associated with lower pediatric overdose mortality rates. The implementation of Good Samaritan laws is significantly associated with lower pediatric overdose mortality rates. We identified no county-level sociodemographic factors associated with pediatric overdose mortality. The findings indicate that a multi-faceted approach to the reduction of pediatric overdose is necessary.
Sections du résumé
BACKGROUND
We determine trends in fatal pediatric drug overdose from 1999 to 2018 and describe the influence of contextual factors and policies on such overdoses.
METHODS
Combining restricted CDC mortality files with data from other sources, we conducted between-county multilevel models to examine associations of demographic and socioeconomic characteristics with pediatric overdose mortality and a fixed-effects analysis to identify how changes in contexts and policies over time shaped county-level fatal pediatric overdoses per 100,000 children under 12 years.
RESULTS
Pediatric overdose deaths rose from 0.08/100,000 children in 1999 to a peak of 0.19/100,000 children in 2016, with opioids accounting for an increasing proportion of deaths. Spatial patterns of pediatric overdose deaths are heterogenous. Socioeconomic characteristics are not associated with between-county differences in pediatric overdose mortality. Greater state expenditures on public welfare (B = -0.099; CI: [-0.193, -0.005]) and hospitals (B = -0.222; CI: [-.437, -.007]) were associated with lower pediatric overdose mortality. In years when a Good Samaritan law was in effect, the county-level pediatric overdose rate was lower (B = -0.095; CI: [-0.177, -0.013]).
CONCLUSIONS
Pediatric overdose mortality increased since 1999, peaking in 2016. Good Samaritan laws and investment in hospitals and public welfare may temper pediatric overdoses. Multi-faceted approaches using policy and individual intervention is necessary to reduce pediatric overdose mortality.
IMPACT
Pediatric fatalities from psychoactive substances have risen within the U.S. since 1999. Higher levels of state spending on public welfare and hospitals are significantly associated with lower pediatric overdose mortality rates. The implementation of Good Samaritan laws is significantly associated with lower pediatric overdose mortality rates. We identified no county-level sociodemographic factors associated with pediatric overdose mortality. The findings indicate that a multi-faceted approach to the reduction of pediatric overdose is necessary.
Identifiants
pubmed: 34021271
doi: 10.1038/s41390-021-01567-7
pii: 10.1038/s41390-021-01567-7
pmc: PMC8606008
mid: NIHMS1698966
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1258-1265Subventions
Organisme : NIDA NIH HHS
ID : R21 DA046447
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.
Références
Birnbaum, H. G. et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 12, 657–667 (2011).
pubmed: 21392250
doi: 10.1111/j.1526-4637.2011.01075.x
Dart, R. C. et al. Trends in opioid analgesic abuse and mortality in the United States. N. Engl. J. Med. 372, 241–248 (2015).
pubmed: 25587948
doi: 10.1056/NEJMsa1406143
Hedegaard, H., Miniño, A. M. & Warner, M. Drug overdose deaths in the United States, 1999–2019. NCHS Data Brief, no 394 (National Center for Health Statistics, 2020).
Ciccarone, D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int. J. Drug Pol. 71, 183 (2019).
doi: 10.1016/j.drugpo.2019.01.010
Jalal, H. et al. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science 361, eaau1184 (2018).
Bohnert, A. S. B. et al. Overdose and adverse drug event experiences among adult patients in the emergency department. Addict. Behav. 86, 66–72 (2018).
pubmed: 29198490
doi: 10.1016/j.addbeh.2017.11.030
Martins, S. S. et al. Prescription opioid use disorder and heroin use among youth nonmedical prescription opioid users from 2002 to 2014. Addict. Behav. 65, 236–241 (2017).
pubmed: 27614657
doi: 10.1016/j.addbeh.2016.08.033
Whiteside, L. K. et al. Nonmedical prescription opioid and sedative use among adolescents in the emergency department. Pediatrics 132, 825–832 (2013).
pubmed: 24167166
pmcid: 3813392
doi: 10.1542/peds.2013-0721
Allen, J. D. et al. Prescription opioid exposures among children and adolescents in the United States: 2000–2015. Pediatrics 139, e20163382 (2017).
pubmed: 28320869
doi: 10.1542/peds.2016-3382
Lovegrove, M. C., Weidle, N. J. & Budnitz, D. S. Trends in emergency department visits for unsupervised pediatric medication exposures, 2004–2013. Pediatrics 136, e821–e829 (2015).
pubmed: 26347435
doi: 10.1542/peds.2015-2092
Gaither, J. R., Shabanova, V. & Leventhal, J. M. US national trends in pediatric deaths from prescription and illicit opioids, 1999-2016. JAMA Netw. Open 1, e186558 (2018).
pubmed: 30646334
pmcid: 6324338
doi: 10.1001/jamanetworkopen.2018.6558
Wang, G. S., Olsen, H., Severtson, G., Green, J. L. & Dart, R. C. The impact of the prescription opioid epidemic on young children: trends and mortality. Drug Alcohol Depend. 211, 107924 (2020).
pubmed: 32178937
doi: 10.1016/j.drugalcdep.2020.107924
Patrick, S. W., Davis, M. M., Lehmann, C. U. & Cooper, W. O. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J. Perinatol. 35, 650–655 (2015).
pubmed: 25927272
pmcid: 4520760
doi: 10.1038/jp.2015.36
Tolia, V. N. et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N. Engl. J. Med. 372, 2118–2126 (2015).
pubmed: 25913111
doi: 10.1056/NEJMsa1500439
Patrick, S. W. et al. Improving care for neonatal abstinence syndrome. Pediatrics 137, e20153835 (2016).
pubmed: 27244809
pmcid: 4845877
doi: 10.1542/peds.2015-3835
Gummin, D. D. et al. 2018 Annual report of the American Association of Poison control centers’ National Poison Data System (NPDS): 36th annual report. Clin. Toxicol. 57, 1220–1413 (2019).
doi: 10.1080/15563650.2019.1677022
Groenewald, C. B., Rabbitts, J. A., Gebert, T. & Palermo, T. M. Trends in opioid prescriptions among children and adolescents in the United States: a nationally representative study from 1996 to 2012. Pain 157, 1021–1027 (2016).
pubmed: 26716995
pmcid: 4943214
doi: 10.1097/j.pain.0000000000000475
Bailey, J. E., Campagna, E. & Dart, R. C. The underrecognized toll of prescription opioid abuse on young children. Ann. Emerg. Med. 53, 419–424 (2009).
pubmed: 18774623
doi: 10.1016/j.annemergmed.2008.07.015
Finkelstein, Y. et al. Overdose risk in young children of women prescribed opioids. Pediatrics 139, e20162887 (2017).
pubmed: 28219963
doi: 10.1542/peds.2016-2887
Burghardt, L. C. et al. Adult prescription drug use and pediatric medication exposures and poisonings. Pediatrics 132, 18–27 (2013).
pubmed: 23733792
pmcid: 4074615
doi: 10.1542/peds.2012-2978
Voepel-Lewis, T., Wagner, D. & Tait, A. R. Leftover prescription opioids after minor procedures: an unwitting source for accidental overdose in children. JAMA Pediatr. 169, 497–498 (2015).
pubmed: 25798880
doi: 10.1001/jamapediatrics.2014.3583
Graham, J., Leonard, J., Banerji, S. & Wang, G. S. Illicit drug exposures in young pediatric patients reported to the National Poison Data System, 2006-2016. J. Pediatr. 219, 254–258 (2020).
pubmed: 31952846
doi: 10.1016/j.jpeds.2019.11.004
Yin, S. Malicious use of pharmaceuticals in children. J. Pediatr. 157, 832–836 (2010).
pubmed: 20650468
doi: 10.1016/j.jpeds.2010.05.040
Kane, J. M., Colvin, J. D., Bartlett, A. H. & Hall, M. Opioid-related critical care resource use in US children’s hospitals. Pediatrics 141, e20173335 (2018).
pubmed: 29507166
doi: 10.1542/peds.2017-3335
Davis, C. S. & Carr, D. Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug Alcohol Depend. 157, 112–120 (2015).
pubmed: 26507172
doi: 10.1016/j.drugalcdep.2015.10.013
Davis, C. S. & Carr, D. State legal innovations to encourage naloxone dispensing. J. Am. Pharm. Assoc. 57, S180–S184 (2017).
doi: 10.1016/j.japh.2016.11.007
Fishman, S. M., Papazian, J. S., Gonzalez, S., Riches, P. S. & Gilson, A. Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain. Pain Med. 5, 309–324 (2004).
pubmed: 15367312
doi: 10.1111/j.1526-4637.2004.04049.x
Gugelmann, H. M. & Perrone, J. Can prescription drug monitoring programs help limit opioid abuse? JAMA 306, 2258–2259 (2011).
pubmed: 22110107
doi: 10.1001/jama.2011.1712
Haegerich, T. M., Paulozzi, L. J., Manns, B. J. & Jones, C. M. What we know, and don’t know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend. 145, 34–47 (2014).
pubmed: 25454406
pmcid: 6557270
doi: 10.1016/j.drugalcdep.2014.10.001
Wheeler, E., Davidson, P. J., Jones, T. S. & Irwin, K. S. Community-based opioid overdose prevention programs providing naloxone—United States, 2010. MMWR Morb. Mortal. Wkly Rep. 61, 101 (2012).
Carlson, R. G., Nahhas, R. W., Martins, S. S. & Daniulaityte, R. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: a natural history study. Drug Alcohol Depend. 160, 127–134 (2016).
pubmed: 26785634
pmcid: 4767561
doi: 10.1016/j.drugalcdep.2015.12.026
Mars, S. G., Bourgois, P., Karandinos, G., Montero, F. & Ciccarone, D. “Every ‘never’ I ever said came true”: transitions from opioid pills to heroin injecting. Int. J. Drug Pol. 25, 257–266 (2014).
doi: 10.1016/j.drugpo.2013.10.004
Powell, D., Pacula, R. L. & Jacobson, M. Do medical marijuana laws reduce addictions and deaths related to pain killers? J. Health Econ. 58, 29–42 (2018).
pubmed: 29408153
pmcid: 7867411
doi: 10.1016/j.jhealeco.2017.12.007
Scholl, L., Seth, P., Kariisa, M., Wilson, N. & Baldwin, G. Drug and opioid-involved overdose deaths — United States, 2013–2017. MMWR Morb. Mortal. Wkly Rep. 67, 1419 (2019).
Allison, P. Fixed Effects Regression Models (SAGE, 2009).
Halaby, C. N. Panel models in sociological research: theory into practice. Annu. Rev. Sociol. 30, 507–544 (2004).
doi: 10.1146/annurev.soc.30.012703.110629
Winship, C. & Morgan, S. L. The estimation of causal effects from observational data. Annu. Rev. Sociol. 25, 659–706 (1999).
doi: 10.1146/annurev.soc.25.1.659
Rudd, R. A., Seth, P., David, F. & Scholl, L. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb. Mortal. Wkly Rep. 65, 1445–1452 (2016).
pubmed: 28033313
doi: 10.15585/mmwr.mm655051e1
Eckenrode, J., Smith, E. G., McCarthy, M. E. & Dineen, M. Income inequality and child maltreatment in the United States. Pediatrics 133, 454–461 (2014).
pubmed: 24515511
doi: 10.1542/peds.2013-1707
Kenney, G. M., Long, S. K. & Luque, A. Health reform in Massachusetts cut the uninsurance rate among children in half. Health Aff. 29, 1242–1247 (2010).
doi: 10.1377/hlthaff.2010.0314
Post, S., Spiller, H. A., Casavant, M. J., Chounthirath, T. & Smith, G. A. Buprenorphine exposures among children and adolescents reported to US poison control centers. Pediatrics 142, e20173652 (2018).
pubmed: 29941678
doi: 10.1542/peds.2017-3652
Budnitz, D. S. & Salis, S. Preventing medication overdoses in young children: an opportunity for harm elimination. Pediatrics 127, e1597–e1599 (2011).
pubmed: 21555494
doi: 10.1542/peds.2011-0926
Egan, K. L. et al. Disposal of prescription drugs by parents of middle and high school students. J. Child Adolesc. Subs. Abus. 28, 92–98 (2019).
doi: 10.1080/1067828X.2019.1590272
Rodgers, G. B. The safety effects of child-resistant packaging for oral prescription drugs: two decades of experience. JAMA 275, 1661–1665 (1996).
pubmed: 8637140
doi: 10.1001/jama.1996.03530450051032
Hampp, C. et al. The role of unit-dose child-resistant packaging in unintentional childhood exposures to buprenorphine–naloxone tablets. Drug Saf. 43, 189–191 (2020).
pubmed: 31745829
doi: 10.1007/s40264-019-00883-6
Wang, G. S., Severtson, S. G., Bau, G. E., Dart, R. C. & Green, J. L. Unit-dose packaging and unintentional buprenorphine-naloxone exposures. Pediatrics 141, e20174232 (2018).
Centers for Disease Control and Prevention. “Up and Away” campaign. https://www.cdc.gov/medicationsafety/protect/campaign.html (2020).
Buchanich, J. M., Balmert, L. C., Williams, K. E. & Burke, D. S. The effect of incomplete death certificates on estimates of unintentional opioid-related overdose deaths in the United States, 1999-2015. Public Health Rep. 133, 423–431 (2018).
pubmed: 29945473
pmcid: 6055296
doi: 10.1177/0033354918774330